Percentage and origin of CMV-specific CTLs in time
. | . | . | CD8+ tetramer T cells (% recipient)* . | . | . | ||
|---|---|---|---|---|---|---|---|
| Patient . | CMV donor . | Graft . | 3 mo . | 7-12 mo . | 2-3 y . | ||
| 1 | + | Re | 2.3 (0) | – | – | ||
| 2 | + | Re | 4.4 (0) | – | – | ||
| 3 | + | De | 10 (100) | 3.5 (100) | 1.5 (100) | ||
| 4 | + | De | 3.7 (100) | 3.8 (100) | – | ||
| 5 | + | De | 2.3 (100) | 0.5 (100) | – | ||
| 6 | + | De | 3.1 (ND) | 1.1 (80) | 0.6 (60) | ||
| 7 | + | De | 2.3 (90) | – | 2.7 (90) | ||
| 8 | + | De | 16 (ND) | 3 (90) | 3 (70) | ||
| 9 | + | De | 13 (0) | – | – | ||
| 10 | + | De | 2.3 (0) | – | – | ||
| 11 | – | Re | 0 | 0 | 0 | ||
| 12 | – | Re | 0 | 0 | – | ||
| 13 | – | Re | 10 (0) | 6.3 (ND) | – | ||
| 14 | – | Re | 0 | 0 | – | ||
| 15 | – | Re | 0 | 0 | 1.3 (0) | ||
| 16 | – | De | 3.5 (100) | 1.2 (100) | – | ||
| 17 | – | De | 8 (100) | 6 (100) | 4.5 (100) | ||
. | . | . | CD8+ tetramer T cells (% recipient)* . | . | . | ||
|---|---|---|---|---|---|---|---|
| Patient . | CMV donor . | Graft . | 3 mo . | 7-12 mo . | 2-3 y . | ||
| 1 | + | Re | 2.3 (0) | – | – | ||
| 2 | + | Re | 4.4 (0) | – | – | ||
| 3 | + | De | 10 (100) | 3.5 (100) | 1.5 (100) | ||
| 4 | + | De | 3.7 (100) | 3.8 (100) | – | ||
| 5 | + | De | 2.3 (100) | 0.5 (100) | – | ||
| 6 | + | De | 3.1 (ND) | 1.1 (80) | 0.6 (60) | ||
| 7 | + | De | 2.3 (90) | – | 2.7 (90) | ||
| 8 | + | De | 16 (ND) | 3 (90) | 3 (70) | ||
| 9 | + | De | 13 (0) | – | – | ||
| 10 | + | De | 2.3 (0) | – | – | ||
| 11 | – | Re | 0 | 0 | 0 | ||
| 12 | – | Re | 0 | 0 | – | ||
| 13 | – | Re | 10 (0) | 6.3 (ND) | – | ||
| 14 | – | Re | 0 | 0 | – | ||
| 15 | – | Re | 0 | 0 | 1.3 (0) | ||
| 16 | – | De | 3.5 (100) | 1.2 (100) | – | ||
| 17 | – | De | 8 (100) | 6 (100) | 4.5 (100) | ||
Re indicates T cell replete; De, T cell depleted; and ND, not done.
Percentage of the CD8+ T cells binding tetramers (percentage of recipient cells in the tetramer-positive cells)